Diagnostic Rentability of Screening for Associated Conditions in Calcium Pyrophosphate Deposition Disease Patients

This study has been completed.

First Received: March 26, 2007 Last Updated: March 27, 2007 History of Changes

Sponsor:	Sociedade Galega de Reumatoloxía
Information provided by:	Sociedade Galega de Reumatoloxía
ClinicalTrials.gov Identifier:	NCT00453128

Purpose

The purpose of this study is to determine whether thorough analytical evaluation is useful to diagnose metabolic conditions associated to calcium pyrophosphate deposition disease.

Condition
Chondrocalcinosis

Study Type:	Observational
Study Design:	Natural History, Longitudinal, Case Control, Prospective Study
Official Title:	Appraisal of the Diagnostic Rentability of Thorough Analytical Screening Searching Associated Conditions in Patients Newly Diagnosed With Calcium Pyrophosphate Dihydrate Deposition Disease

Resource links provided by NLM:

MedlinePlus related topics: Calcium

Drug Information available for: Calcium gluconate

U.S. FDA Resources

Further study details as provided by Sociedade Galega de Reumatoloxía:

Estimated Enrollment:	240
Study Start Date:	January 1997
Study Completion Date:	December 2006

Detailed Description:

The diagnostic usefulness of screening for hyperparathyroidism, hemochromatosis, hypothyroidism and hypophosphatasia in patients diagnosed with calcium pyrophosphate dihydrate (CPPD) deposition disease is uncertain.

Patients diagnosed with CPPD deposition disease were compared to patients with rheumatoid arthritis and psoriatic arthritis over a 9-year period. All patients were prospectively followed for at least 12 months. Serum calcium, phosphorus, alkaline phosphatase, thyroid-stimulating hormone, ferritin, iron, and total iron binding capacity were determined in all patients.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients diagnosed as having calcium pyrophosphate dihydrate deposition disease.

Exclusion Criteria:

Patients mimicking a rheumatoid arthritis disease, with positive rheumatoid factor or with psoriasis.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00453128

Locations

Spain, Pontevedra
Meixoeiro Hospital
Vigo, Pontevedra, Spain, 36214

Sponsors and Collaborators

Sociedade Galega de Reumatoloxía

Investigators

Principal Investigator:

José M Pego-Reigosa, MD, PhD

Meixoeiro Hospital, Vigo (Pontevedra) SPAIN

More Information

No publications provided

Study ID Numbers:	SGR1
Study First Received:	March 26, 2007
Last Updated:	March 27, 2007
ClinicalTrials.gov Identifier:	NCT00453128 History of Changes
Health Authority:	Spain: Ministry of Health

Keywords provided by Sociedade Galega de Reumatoloxía:

Calcium Pyrophosphate
associated conditions

Additional relevant MeSH terms:

Musculoskeletal Diseases
Chondrocalcinosis
Joint Diseases
Arthritis

ClinicalTrials.gov processed this record on February 08, 2010